Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
Public ClinicalTrials.gov record NCT01058005. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis
Study identification
- NCT ID
- NCT01058005
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Biogen
- Industry
- Enrollment
- 84 participants
Conditions and interventions
Conditions
Interventions
- BG00002 (natalizumab) Drug
- interferon beta-1a Drug
- glatiramer acetate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2010
- Primary completion
- Mar 31, 2012
- Completion
- Mar 31, 2012
- Last update posted
- Sep 2, 2014
2010 – 2012
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Cullman | Alabama | — | — |
| Research Site | Phoenix | Arizona | — | — |
| Research Site | Fort Collins | Colorado | — | — |
| Research Site | Maitland | Florida | — | — |
| Research Site | St. Petersburg | Florida | — | — |
| Research Site | Tampa | Florida | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Lexington | Kentucky | — | — |
| Research Site | New Orleans | Louisiana | — | — |
| Research Site | Detroit | Michigan | — | — |
| Research Site | Patchogue | New York | — | — |
| Research Site | Charlotte | North Carolina | — | — |
| Research Site | Akron | Ohio | — | — |
| Research Site | Franklin | Tennessee | — | — |
| Research Site | Knoxville | Tennessee | — | — |
| Research Site | Round Rock | Texas | — | — |
| Research Site | Norfolk | Virginia | — | — |
| Research Site | Kirkland | Washington | — | — |
| Research Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01058005, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2014 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01058005 live on ClinicalTrials.gov.